Skip to content

A Study of Time-Restricted Eating in Childhood Cancer Survivors

Decreasing Cardiometabolic Risk in Childhood Cancer Survivors: The STRENGTH (Survivors Engaged in Time-Restricted EatiNG After THerapy) Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07009288
Enrollment
300
Registered
2025-06-06
Start date
2025-05-27
Completion date
2031-05-01
Last updated
2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Cancer Survivors

Brief summary

This study will look at whether motivational sessions (including regular calls with a trained health coach) in combination with time-restricted eating (TRE) is an effective way to achieve weight loss and lower cardiometabolic risk in adult survivors of childhood cancer. The researchers will look at how effective this intervention is compared to the usual approach, which is to review educational materials and measure weight once a month. This study will not provide treatment for any disease or cancer.

Interventions

OTHERChildren's Oncology Group Heart Health Link

Educational materials on healthy lifestyle behaviors.

OTHERMonthly weights

Weight (kg): measured remotely via Withings Body + scale, Height, weight, waist circumference, BP, and % body fat

OTHERFasting

(14-hour fast x 2 weeks; 15-hour fast x- 1 week; 16-hour fast for the remainder of the active intervention)

OTHERCalls

Month 1-3: Bi-weekly call using motivational interviewing Months 4-6: Monthly call using motivational interviewing Support via SMS text

OTHERParticipant Questionnaires

Questions on worry, perceived self-efficacy, health beliefs and knowledge of late effects (adapted from EQUAL study), Behavioral Risk Factor Surveillance System, Physical Activity Questionnaire, Link to Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool with accompanying sleep module

Glucose, insulin, hemoglobin A1c, lipids. Measured remotely in the fasting state via dried blood spots in the participant's home.

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Masking description

Team members conducting data analysis will be blinded to each participant's assignment.

Intervention model description

This is a phase 2b randomized controlled trial of a TRE intervention among childhood cancer survivor participants with overweight and obesity in the Childhood Cancer Survivor Study (CCSS), designed according to the ORBIT model for behavioral intervention development.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Enrolled in the Childhood Cancer Survivor Study (a cohort of 5+ year survivors of childhood cancer diagnosed at age \< 21 between 1970-1999 at 31 participating institutions in North America) * Are ≥18 years old * Self-reported body mass index ≥ 25 kg/m2 * Are not pregnant or do not intend to become pregnant in the next year * Stable weight over the past 3 months (+/- 10 pounds) * If on oral medication for insulin resistance (ie, metformin), elevated blood pressure, or dyslipidemia, medication dose must be stable (ie, unchanged \> 3 months) * Have internet access (can be via smartphone or computer). If neither device is available, the study can loan participants a Wi-Fi enabled device.

Exclusion criteria

* Do not reside in the United States * Do not speak English * Eating window \< 12 hours per 24-hour day * On insulin or GLP-1 agonist * Diagnosis of type 1 diabetes mellitus * Enrolled in a formal weight management program or other weight loss trial * History of an eating disorder

Design outcomes

Primary

MeasureTime frame
Percent change in weightat 12 months

Secondary

MeasureTime frameDescription
Change in glucoseup to 12 monthsvia dried blood spots
Change in insulinup to 12 monthsvia dried blood spots
Change in HbA1cup to 12 monthsvia dried blood spots

Countries

United States

Contacts

CONTACTDanielle Friedman, MD
friedmad@mskcc.org1-833-MSK-KIDS
CONTACTChaya Moskowitz, PhD
646-227-3607
PRINCIPAL_INVESTIGATORDanielle Friedman, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026